ArticleThe Lancet regional health. Europe2024

Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study.

Adrien Rousseau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.